ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för vandetanib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

64 träffar

Bibliografisk träff 2009-07-01

Corneal verticillata after dual anti-epidermal growth factor receptor and anti-vascular endothelial growth factor receptor 2 therapy (vandetanib) for anaplastic astrocytoma.

Yeh S, Fine HA, Smith JA.

Cornea · research support, n.i.h., intramural; research support, non-u.s. gov't; research-article; journal article; case reports · DOI 10.1097/ico.0b013e3181922146

Bibliografisk träff 2009-04-25

ZD6474 inhibits Src kinase leading to apoptosis of imatinib-resistant K562 cells.

Jia HY, Wu JX, Zhu XF, Chen JM, Yang SP, Yan HJ, Tan L, Zeng YX, Huang W.

Leuk Res · research support, non-u.s. gov't; journal article · DOI 10.1016/j.leukres.2009.03.033

Bibliografisk träff 2009-04-06

Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.

Morabito A, Piccirillo MC, Falasconi F, De Feo G, Del Giudice A, Bryce J, Di Maio M, De Maio E, Normanno N, Perrone F.

Oncologist · review; journal article · DOI 10.1634/theoncologist.2008-0261

Bibliografisk träff 2009-03-30

Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study.

Natale RB, Bodkin D, Govindan R, Sleckman BG, Rizvi NA, Capó A, Germonpré P, Eberhardt WE, Stockman PK, Kennedy SJ, Ranson M.

J Clin Oncol · clinical trial, phase ii; comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1200/jco.2008.18.6015

Bibliografisk träff 2009-02-10

Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner.

Flaig TW, Su LJ, McCoach C, Li Y, Raben D, Varella-Garcia M, Bemis LT.

BJU Int · journal article; research support, n.i.h., extramural · DOI 10.1111/j.1464-410x.2009.08367.x

Bibliografisk träff 2009-01-01

[Advances in the treatment of thyroid cancer in the era of molecularly targeted therapies].

Malouf G, Baudin E, Soria JC, Schlumberger M.

Bull Cancer · review; journal article; english abstract · DOI 10.1684/bdc.2008.0798

Bibliografisk träff 2008-12-16

An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer.

de Boer R, Humblet Y, Wolf J, Nogová L, Ruffert K, Milenkova T, Smith R, Godwood A, Vansteenkiste J.

Ann Oncol · research support, non-u.s. gov't; multicenter study; clinical trial, phase i; journal article · DOI 10.1093/annonc/mdn674

Bibliografisk träff 2008-11-11

Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer.

Michael M, Gibbs P, Smith R, Godwood A, Oliver S, Tebbutt N.

Invest New Drugs · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1007/s10637-008-9182-8

Bibliografisk träff 2008-10-20

Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.

Heymach JV, Paz-Ares L, De Braud F, Sebastian M, Stewart DJ, Eberhardt WE, Ranade AA, Cohen G, Trigo JM, Sandler AB, Bonomi PD, Herbst RS, Krebs AD, Vasselli J, Johnson BE.

J Clin Oncol · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1200/jco.2008.17.3138

Bibliografisk träff 2008-08-01

Vandetanib inhibits growth of adenoid cystic carcinoma in an orthotopic nude mouse model.

Choi S, Sano D, Cheung M, Zhao M, Jasser SA, Ryan AJ, Mao L, Chen WT, El-Naggar AK, Myers JN.

Clin Cancer Res · research support, non-u.s. gov't; journal article; research support, n.i.h., extramural · DOI 10.1158/1078-0432.ccr-08-0245

Bibliografisk träff 2008-01-29

Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model.

Sandström M, Johansson M, Bergström P, Bergenheim AT, Henriksson R.

J Neurooncol · research support, non-u.s. gov't; journal article · DOI 10.1007/s11060-008-9527-3

Bibliografisk träff 2007-11-01

Induction of cell cycle arrest and apoptosis in human nasopharyngeal carcinoma cells by ZD6474, an inhibitor of VEGFR tyrosine kinase with additional activity against EGFR tyrosine kinase.

Xiao X, Wu J, Zhu X, Zhao P, Zhou J, Liu QQ, Zheng L, Zeng M, Liu R, Huang W.

Int J Cancer · research support, non-u.s. gov't; journal article · DOI 10.1002/ijc.22955

Bibliografisk träff 2007-10-02

ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein.

Mi Y, Lou L.

Br J Cancer · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/sj.bjc.6603985

Bibliografisk träff 2007-09-01

Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer.

Heymach JV, Johnson BE, Prager D, Csada E, Roubec J, Pesek M, Spásová I, Belani CP, Bodrogi I, Gadgeel S, Kennedy SJ, Hou J, Herbst RS.

J Clin Oncol · clinical trial, phase ii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1200/jco.2006.10.5122

Bibliografisk träff 2007-03-29

Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts.

Gustafson DL, Frederick B, Merz AL, Raben D.

Cancer Chemother Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1007/s00280-007-0460-5

Bibliografisk träff 2006-11-01

A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors.

Tamura T, Minami H, Yamada Y, Yamamoto N, Shimoyama T, Murakami H, Horiike A, Fujisaka Y, Shinkai T, Tahara M, Kawada K, Ebi H, Sasaki Y, Jiang H, Saijo N.

J Thorac Oncol · research support, non-u.s. gov't; multicenter study; clinical trial, phase i; journal article · DOI 10.1016/s1556-0864(15)31634-8

Bibliografisk träff 2006-10-01

Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy.

Sathornsumetee S, Rich JN.

Drugs Today (Barc) · research support, non-u.s. gov't; review; journal article · DOI 10.1358/dot.2006.42.10.1025318

Bibliografisk träff 2006-08-01

Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases.

Morelli MP, Cascone T, Troiani T, Tuccillo C, Bianco R, Normanno N, Romano M, Veneziani BM, Fontanini G, Eckhardt SG, De Pacido S, Tortora G, Ciardiello F.

J Cell Physiol · comparative study; research support, non-u.s. gov't; evaluation study; journal article · DOI 10.1002/jcp.20666

Bibliografisk träff 2006-07-13

New antiangiogenetic agents and non-small cell lung cancer.

Gridelli C, Rossi A, Maione P.

Crit Rev Oncol Hematol · review; journal article · DOI 10.1016/j.critrevonc.2006.01.008

Bibliografisk träff 2006-01-01

ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy.

Frederick B, Gustafson D, Bianco C, Ciardiello F, Dimery I, Raben D.

Int J Radiat Oncol Biol Phys · journal article · DOI 10.1016/j.ijrobp.2005.05.050

Bibliografisk träff 2006-01-01

ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model.

Matsumori Y, Yano S, Goto H, Nakataki E, Wedge SR, Ryan AJ, Sone S.

Oncol Res · journal article · DOI 10.3727/000000006783981260

Bibliografisk träff 2005-12-01

Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice.

Yano S, Muguruma H, Matsumori Y, Goto H, Nakataki E, Edakuni N, Tomimoto H, Kakiuchi S, Yamamoto A, Uehara H, Ryan A, Ryan A, Sone S.

Clin Cancer Res · research support, non-u.s. gov't; journal article · DOI 10.1158/1078-0432.ccr-05-0674

Bibliografisk träff 2005-11-01

ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors.

Rich JN, Sathornsumetee S, Keir ST, Kieran MW, Laforme A, Kaipainen A, McLendon RE, Graner MW, Rasheed BK, Wang L, Reardon DA, Ryan AJ, Wheeler C, Dimery I, Bigner DD, Friedman HS.

Clin Cancer Res · comparative study; research support, non-u.s. gov't; journal article; research support, n.i.h., extramural · DOI 10.1158/1078-0432.ccr-05-0319

Bibliografisk träff 2005-09-02

The effects of ZD6474, an inhibitor of VEGF signaling, on cutaneous wound healing in mice.

Ko J, Ross J, Awad H, Hurwitz H, Klitzman B.

J Surg Res · research support, non-u.s. gov't; journal article; research support, n.i.h., extramural · DOI 10.1016/j.jss.2005.05.006

Bibliografisk träff 2005-09-01

Phase II data with ZD6474, a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, in previously treated advanced non-small-cell lung cancer.

Lee D.

Clin Lung Cancer · review; journal article · DOI 10.1016/s1525-7304(11)70394-1

Bibliografisk träff 2005-06-01

ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity.

Ryan AJ, Wedge SR.

Br J Cancer · research-article; review; journal article · DOI 10.1038/sj.bjc.6602603

Bibliografisk träff 2004-12-01

Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models.

Taguchi F, Koh Y, Koizumi F, Tamura T, Saijo N, Nishio K.

Cancer Sci · journal article · DOI 10.1111/j.1349-7006.2004.tb03187.x

Bibliografisk träff 2004-12-01

Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474.

Arao T, Fukumoto H, Takeda M, Tamura T, Saijo N, Nishio K.

Cancer Res · research support, non-u.s. gov't; journal article · DOI 10.1158/0008-5472.can-04-2360

Bibliografisk träff 2004-12-01

ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity.

Williams KJ, Telfer BA, Brave S, Kendrew J, Whittaker L, Stratford IJ, Wedge SR.

Clin Cancer Res · comparative study; journal article · DOI 10.1158/1078-0432.ccr-04-1147

Bibliografisk träff 2004-12-01

Combination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approach.

Nicholson B, Gulding K, Conaway M, Wedge SR, Theodorescu D.

Clin Cancer Res · research support, u.s. gov't, p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1158/1078-0432.ccr-04-0902